Lidocaine-d10 N-Oxide

Lidocaine-d10 N-Oxide

• CAS Number: 851528-10-4
• UNSPSC Description: N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2].
• Target Antigen: Apoptosis; ERK; Isotope-Labeled Compounds; MEK; NF-κB; Sodium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;MAPK/ERK Pathway;Membrane Transporter/Ion Channel;NF-κB;Others;Stem Cell/Wnt
• Field of Research: Cancer; Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: N(C(CN(C(C([2H])([2H])[2H])([2H])[2H])(C(C([2H])([2H])[2H])([2H])[2H])=O)=O)C1=C(C)C=CC=C1C
• Molecular Weight: 260.40
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6.|[3]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11.|[4]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported